In a market obsessed with flashy headlines, Pepticom operates in the shadows of the algorithm, using artificial intelligence to design novel therapeutic peptides. They aren't building the next consumer app; they are coding the blueprints for the next generation of life-saving drugs.

"They aren't discovering drugs; they are designing the logic that discovers them."

The company's leadership team, led by Founder Immanuel Lerner and Chief Biologist Shaul Lerner, bridges the gap between engineering and biology. Their keyword strategy reveals a focus on high-intent, niche queries like 'peptide technologies' (3,700 monthly volume) rather than broad consumer terms. They are targeting the experts, not the public.

• Proprietary AI algorithms for peptide design (not just data analysis).
• A hybrid team structure: heavy on science, light on overhead.
• Focus on 'undruggable' targets that traditional pharma ignores.